+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID07775924

Evaluating the Safety and Effectiveness of GIA632 Compared to Placebo in Moderate to Severe Cutaneous Lichen Planus With a Long-Term Extension

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

259

Participants Needed

21

Research Sites

64 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of GIA632 in people with moderate to severe cutaneous lichen planus cLP. The goal is to find the best dose of GIA632 to use in future larger studies. This is a Phase IIb trial that includes multiple dosing regimens and compares GIA632 with placebo. Participants will be randomly assigned to receive either GIA632 at one of several dose levels or a matching placebo during a 16-week double-blind treatment period. After this core period, participants can continue in a 52-week extension phase to further assess safety and effects. Finally, there is a 12-week safety follow-up period after treatment ends. During the study, participants will be assessed regularly using the Investigator Global Assessment IGA scale, peak itch rating scales, and Lichen Planus Activity and Damage Index LiPADI scores. Safety will be monitored through adverse event reports for up to 80 weeks. The total study duration includes screening, treatment, extension, and follow-up phases lasting over a year.

CONDITIONS

Brief Title

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here